Congenital Adrenal Hyperplasia - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Congenital Adrenal Hyperplasia – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Congenital Adrenal Hyperplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Congenital Adrenal Hyperplasia: Overview
Congenital adrenal hyperplasia (CAH) is a group of rare inherited autosomal recessive disorders characterized by a deficiency of one of the enzymes needed to make specific hormones. CAH effects the adrenal glands located at the top of each kidney. Normally, the adrenal glands are responsible for producing three different hormones: 1. corticosteroids, which gauge the body’s response to illness or injury; 2. mineralocorticoids, which regulate salt and water levels; and 3. androgens, which are male sex hormones. An enzyme deficiency will make the body unable to produce one or more of these hormones, which in turn will result in the overproduction of another type of hormone precursor in order to compensate for the loss. The most common cause of CAH is the absence of the enzyme 21-hydroxylase. Different mutations in the gene responsible for 21-hydroxylase result in different levels of the enzyme, producing a spectrum of effects. Genetic testing for the gene mutations associated with the various forms of CAH is available, but is most often performed when pre-pregnancy genetic counseling is indicated, after an endocrinologist confirms the diagnosis through blood hormone tests, or if results of hormone tests are not definitive. Treatment of CAH varies greatly depending on the type and severity. CAH cannot be cured, but it can be effectively treated. The primary goal of treating classical CAH is to reduce the excess androgen production and replace the deficient hormones.
'Congenital Adrenal Hyperplasia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Congenital Adrenal Hyperplasia pipeline landscape is provided which includes the disease overview and Congenital Adrenal Hyperplasia treatment guidelines. The assessment part of the report embraces, in depth Congenital Adrenal Hyperplasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Congenital Adrenal Hyperplasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Congenital Adrenal Hyperplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Congenital Adrenal Hyperplasia Emerging Drugs
Further product details are provided in the report.
Congenital Adrenal Hyperplasia: Therapeutic Assessment
This segment of the report provides insights about the different Congenital Adrenal Hyperplasia drugs segregated based on following parameters that define the scope of the report, such as:
Congenital Adrenal Hyperplasia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Congenital Adrenal Hyperplasia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Congenital Adrenal Hyperplasia drugs.
Congenital Adrenal Hyperplasia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Congenital Adrenal Hyperplasia – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Congenital Adrenal Hyperplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Congenital Adrenal Hyperplasia: Overview
Congenital adrenal hyperplasia (CAH) is a group of rare inherited autosomal recessive disorders characterized by a deficiency of one of the enzymes needed to make specific hormones. CAH effects the adrenal glands located at the top of each kidney. Normally, the adrenal glands are responsible for producing three different hormones: 1. corticosteroids, which gauge the body’s response to illness or injury; 2. mineralocorticoids, which regulate salt and water levels; and 3. androgens, which are male sex hormones. An enzyme deficiency will make the body unable to produce one or more of these hormones, which in turn will result in the overproduction of another type of hormone precursor in order to compensate for the loss. The most common cause of CAH is the absence of the enzyme 21-hydroxylase. Different mutations in the gene responsible for 21-hydroxylase result in different levels of the enzyme, producing a spectrum of effects. Genetic testing for the gene mutations associated with the various forms of CAH is available, but is most often performed when pre-pregnancy genetic counseling is indicated, after an endocrinologist confirms the diagnosis through blood hormone tests, or if results of hormone tests are not definitive. Treatment of CAH varies greatly depending on the type and severity. CAH cannot be cured, but it can be effectively treated. The primary goal of treating classical CAH is to reduce the excess androgen production and replace the deficient hormones.
'Congenital Adrenal Hyperplasia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Congenital Adrenal Hyperplasia pipeline landscape is provided which includes the disease overview and Congenital Adrenal Hyperplasia treatment guidelines. The assessment part of the report embraces, in depth Congenital Adrenal Hyperplasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Congenital Adrenal Hyperplasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Congenital Adrenal Hyperplasia R&D. The therapies under development are focused on novel approaches to treat/improve Congenital Adrenal Hyperplasia.
This segment of the Congenital Adrenal Hyperplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Congenital Adrenal Hyperplasia Emerging Drugs
- Chronocort: Diurnal Group plc
Further product details are provided in the report.
Congenital Adrenal Hyperplasia: Therapeutic Assessment
This segment of the report provides insights about the different Congenital Adrenal Hyperplasia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Congenital Adrenal Hyperplasia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Congenital Adrenal Hyperplasia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Congenital Adrenal Hyperplasia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Congenital Adrenal Hyperplasia drugs.
Congenital Adrenal Hyperplasia Report Insights
- Congenital Adrenal Hyperplasia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Congenital Adrenal Hyperplasia drugs?
- How many Congenital Adrenal Hyperplasia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Congenital Adrenal Hyperplasia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Congenital Adrenal Hyperplasia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Congenital Adrenal Hyperplasia and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Congenital Adrenal Hyperplasia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Registered)
Comparative Analysis
Chronocort: Diurnal Group plc
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
SPR001: spruce Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early stage products (Phase I/II)
Comparative Analysis
AAV BBP-631: Adrenas Therapeutics Inc
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Congenital Adrenal Hyperplasia Key Companies
Congenital Adrenal Hyperplasia Key Products
Congenital Adrenal Hyperplasia- Unmet Needs
Congenital Adrenal Hyperplasia- Market Drivers and Barriers
Congenital Adrenal Hyperplasia- Future Perspectives and Conclusion
Congenital Adrenal Hyperplasia Analyst Views
Congenital Adrenal Hyperplasia Key Companies
Appendix
Executive Summary
Congenital Adrenal Hyperplasia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Registered)
Comparative Analysis
Chronocort: Diurnal Group plc
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
SPR001: spruce Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early stage products (Phase I/II)
Comparative Analysis
AAV BBP-631: Adrenas Therapeutics Inc
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Congenital Adrenal Hyperplasia Key Companies
Congenital Adrenal Hyperplasia Key Products
Congenital Adrenal Hyperplasia- Unmet Needs
Congenital Adrenal Hyperplasia- Market Drivers and Barriers
Congenital Adrenal Hyperplasia- Future Perspectives and Conclusion
Congenital Adrenal Hyperplasia Analyst Views
Congenital Adrenal Hyperplasia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Congenital Adrenal Hyperplasia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Congenital Adrenal Hyperplasia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Congenital Adrenal Hyperplasia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Congenital Adrenal Hyperplasia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products